An insight into how the financial market sees ... - CLL Support

CLL Support

22,532 members38,709 posts

An insight into how the financial market sees the development of new CLL drugs

AussieNeil profile image
AussieNeilAdministrator
2 Replies

AbbVie developed a novel BCL-2 inhibitor drug named ABT-263 for treating CLL, then used the knowledge gained from phase I trials to develop the improved drug ABT-199. Trials were suspended this month when two patients unfortunately died from Tumor Lysis Syndrome:

bloomberg.com/news/2013-02-...

It's interesting to read that this company has one drug delivering over half of the company's income and they need another to reduce business risk.

fool.com/investing/general/...

How desperate a company might be for a new income stream isn't something that is likely to be high in the thoughts of those entering trials. Thankfully we do have in place appropriate processes to minimise the risk to patients entering trials and to ensure that a safe dose and delivery protocol, etc, are determined by running them. While it is very disappointing that two CLL patients died from TLS during the ABT-199 trials, the company has acted with appropriate caution despite the likely financial impact. Hopefully the company will be able to successful complete the approval process for ABT-199 as planned and benefit the company shareholders while providing those of us needing treatment with a hopefully better and safer alternative to currently available options.

Written by
AussieNeil profile image
AussieNeil
Administrator
To view profiles and participate in discussions please or .
Read more about...
2 Replies
jangreen profile image
jangreen

Hi I was in a trial. I felt I was given as much information as possible and was please with the care and treatment I received. It will not be untill years to come whether its been effective or not. Its always the risk you take.

Oleboyredw-uk profile image
Oleboyredw-uk

Having a large percentage of a company income from one source is a bad place to be for them. I''ve seen the effect on share price of a company where 60% of their income came from purchases by three big companies. Two of those stopped or nearly stopped purchases for a quarter. Big impact on bttom line ad 30% off share price not good.

The message for us... The companies need to research AND deliver new drugs it be healthy themselves. Let's all hope they stay healthy. :-)

Rob

You may also like...

New drug: MS-553 inhibitor for CLL/SLL who develop resistance to BTK inhibitors

alternative treatment option for patients with CLL/SLL who develop resistance to BTK inhibitors....

Any insight as to CAUSES of cll besides 'age'or 'genetics'?

apparently, not much insight besides 'age' on causes of cll. Some have suggested that it can be...

Cost of CLL Drugs in the USA

Why is the cost of drugs such as Imbruvica and Calquence so high in the USA under Medicare? With...

CLL drugs covered in Ontario

me which first line treatment targeted therapy drugs are covered (paid for or reimbursable)? i.e.,...

Cll Drugs and the Immune System

interesting. Can I make the assumption that all of the CLL drug therapies suppress our B cells, or...